Company / Cash & Equivalents
CANNAPHARMARX, INC. Cash & Equivalents History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.8K
FY2025
5-year range
$1.8K / $335.0K
FY2021-FY2025
Trend
-16.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 4 consecutive years, from $334,969 in FY2020 to $1,804 in FY2025.
Based on SEC 10-K filings.
$1,804 in FY2025 with a 10-year CAGR of -3.7%.
Declined from $2,317 to $1,804 over the past 3 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -8.0%
- 5-Year CAGR
- -64.8%
- 10-Year CAGR
- -3.7%
Key checks
Key Insights
- CANNAPHARMARX, INC.'s cash & equivalents has declined for 4 consecutive years.
- 5-year CAGR of -64.8%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 16.3% year-over-year.
- Peak cash & equivalents was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -18.28 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.8K | -16.3% |
| FY2024 | $2.2K | -6.9% |
| FY2022 | $2.3K | -91.7% |
| FY2021 | $27.8K | -91.7% |
| FY2020 | $335.0K | +21552.8% |
| FY2019 | $1.5K | -99.7% |
| FY2018 | $464.1K | - |
| FY2017 | $0 | - |
| FY2016 | $0 | -100.0% |
| FY2015 | $2.6K | -99.8% |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026